Combined organ and hematopoietic cells for transplantation tolerance of hla mismatched grafts
US-2017106086-A1 · Apr 20, 2017 · US
Combined organ and hematopoietic cells for transplantation tolerance of grafts
US11020428B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11020428-B2 |
| Application number | US-201816196806-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 20, 2018 |
| Priority date | Feb 26, 2013 |
| Publication date | Jun 1, 2021 |
| Grant date | Jun 1, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of manufacturing a cellular product for establishing mixed chimerism in a solid organ transplant recipient, the method comprising: obtaining one or more samples comprising CD34+ cells and CD3+ cells; processing the one or more samples to substantially remove platelets and red blood cells; and further processing the one or more samples to produce a cellular product comprising greater than 5×105 CD34+ cells/kg recipient weight, and greater than 1×105 CD3+ cells/kg recipient weight, wherein the cellular product is substantially devoid of platelets and red blood cells. 2. The method of claim 1 , wherein the one or more samples are further processed such that the cellular product comprises at least about 4×106 CD34+ cells/kg recipient weight. 3. The method of claim 1 , wherein the one or more samples are further processed such that the cellular product comprises at least about 1×106 CD3+ cells/kg recipient weight. 4. The method of claim 1 , wherein the one or more samples are further processed such that the cellular product comprises at least about 4×106 CD34+ cells/kg recipient weight and about 1×106 CD3+ cells/kg recipient weight. 5. The method of claim 1 , wherein the one or more samples are further processed such that the cellular product comprises at least about 4×106 CD34+ cells/kg recipient weight and at least about 1×106 CD3+ cells/kg recipient weight. 6. The method of claim 1 , wherein the cellular product is produced such that the CD34+ cells and the CD3+ cells are provided in separate containers. 7. The method of claim 1 , wherein the cellular product is produced such that the CD34+ cells and the CD3+ cells are provided as a mixture in a common container. 8. The method of claim 1 , wherein the CD34+ cells and the CD3+ cells are HLA matched to an HLA type of the solid organ transplant recipient. 9. The method of claim 1 , wherein the CD34+ cells and the CD3+ cells are HLA mismatched to an HLA type of the solid organ transplant recipient. 10. The method of claim 1 , wherein CD34+ cells and the CD3+ cells are from a single apheresis product.
Assignees
Inventors
Classifications
- A61K35/14Primary
Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42) · CPC title
Antigens related to induction of tolerance to non-self · CPC title
Immunosuppressive or immunotolerising · CPC title
T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title
characterised by the cell type used · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11020428B2 cover?
- Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time s…
- Who is the assignee on this patent?
- Univ Leland Stanford Junior
- What technology area does this patent fall under?
- Primary CPC classification A61K35/14. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).